P Ann Onc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from P ann onc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In P Ann Onc Today - Breaking & Trending Today

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

....

United States , Shannonn Westin , P Ann Onc , Division Of Surgery , University Of Texas Md Anderson Cancer Center , Department Of Gynecologic Oncology , Gynecologic Oncology , Reproductive Medicine , Cancer Center , Published October ,

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial. ....

United States , P Ann Onc , Shannonn Westin , Department Of Gynecologic Oncology , University Of Texas Md Anderson Cancer Center , Division Of Surgery , Gynecologic Oncology , Reproductive Medicine , Cancer Center , Published October , Endometrial Cancer , Duo E , Duoe Gog 3041 Engot En10 Trial , Esmo Congress , The University Of Texas Md Anderson Cancer Center ,

Adjuvant Abemaciclib Plus Endocrine Therapy Sustains iDFS, DRFS Benefit in HR+, HER2– Early Breast Cancer

Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer. ....

Eli Lilly , David Hyman , Kaplan Meier , P Ann Onc , Nadia Harbeck , Breast Center , Department Of Gynecology , Cancer Center Munich , Ludwig Maximilians University Hospital , Comprehensive Cancer Center Munich , Lancet Oncology , Monarche Trial , Hr Positive Breast Cancer , Hormone Receptor Positive Breast Cancer , Esmo Congress ,

Pembrolizumab Plus Neoadjuvant Chemotherapy Produces Long-Term Survival Benefits in High-Risk TNBC

Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer. ....

Peter Schmid , P Ann Onc , Centre Of Experimental Cancer Medicine , Barts Cancer Institute , Barts Breast Cancer Centre , Experimental Cancer Medicine , New England Journal , Early Triple Negative Breast , Esmo Congress , Breast Cancer , Phase 3 Keynote 522 Trial ,